New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 16, 2014
07:02 EDTISISIsis Pharmaceuticals reports final Phase 2 data on ISIS-GCGR Rx
Isis Pharmaceuticals announced the final results from its Phase 2 study of ISIS-GCGRRx in patients with type 2 diabetes uncontrolled on stable metformin therapy. In this study, patients in the per protocol population treated with ISIS-GCGRRx in addition to metformin achieved absolute mean reduction in hemoglobin A1c of up to 2.25 percentage points from baseline after only 13 weeks of treatment. Patients receiving placebo had an 0.25 percentage point reduction in HbA1c. In this study, more than half of the PP patients achieved an HbA1c level of less than or equal to 7.0 percent. PP patients treated with ISIS-GCGRRx in this study also achieved a mean reduction of up to 74.9 Ámol/L in fructosamine. In addition, in these patients a mean increase in total GLP-1 of up to 19.97 pmol/L was observed.
News For ISIS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 15, 2014
09:57 EDTISISLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
October 13, 2014
07:12 EDTISISOligonucleotide Therapeutics Society to hold annual meeting
Subscribe for More Information
October 10, 2014
09:00 EDTISISOn The Fly: Pre-market Movers
Subscribe for More Information
05:22 EDTISISIsis Pharmaceuticals reports data from ISIS-SMN Rx Phase 2 study
Subscribe for More Information
October 9, 2014
07:02 EDTISISIsis Pharmaceuticals receives $18M milestone payment from GlaxoSmithKline
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use